{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:21:24Z","timestamp":1793298084664,"version":"4.5.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.medcli.2024.05.004","type":"journal-article","created":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T04:21:13Z","timestamp":1720930873000},"page":"317-322","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Effectiveness and safety of alirocumab and evolocumab for hypercholesterolemia in a population with high cardiovascular risk"],"prefix":"10.1016","volume":"163","author":[{"given":"Montserrat","family":"Bosch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Immaculada","family":"Dan\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ballar\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Marrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillem","family":"Vancells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel","family":"Ortiz-Z\u00fa\u00f1iga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Urquizu-Padilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Rial-Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Lozano-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Rodr\u00edguez-Luna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Filippi-Arriaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ant\u00f2nia","family":"Agust\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2024.05.004_bib0115","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2024.05.004_bib0120","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2024.05.004_bib0125","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.medcli.2024.05.004_bib0130","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/ehjqcco\/qcac009","article-title":"Low-density lipoprotein cholesterol levels exceed the recommended European threshold for PCSK9i initiation: lessons from the HEYMANS study","volume":"8","author":"Ray","year":"2022","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"10.1016\/j.medcli.2024.05.004_bib0135","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. [Informe de Posicionamiento Terap\u00e9utico de Evolocumab (Repatha\u00ae) en hipercolesterolemia]. Available from: https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/IPT_12-2020-evolocumab-Repatha.pdf [accessed 11.07.23]."},{"key":"10.1016\/j.medcli.2024.05.004_bib0140","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. [Informe de Posicionamiento Terap\u00e9utico de Alirocumab (Praluent\u00ae) en hipercolesterolemia]. Available from: https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/IPT_13-2020-alirocumab-Praluent.pdf [accessed 11.07.23]."},{"key":"10.1016\/j.medcli.2024.05.004_bib0145","unstructured":"CatSalut CFT-SISCAT agreement on the use of alirocumab in the treatment of adult patients with primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia. Version 2. Updated July 2019. Available from: https:\/\/catsalut.gencat.cat\/web\/.content\/minisite\/catsalut\/proveidors_professionals\/medicaments_farmacia\/harmonitzacio\/informes\/alirocumab\/acord-CFT-SISCAT-alirocumab.pdf [accessed 11.07.23]."},{"key":"10.1016\/j.medcli.2024.05.004_bib0150","unstructured":"CatSalut CFT-SISCAT agreement on the use of evolocumab in the treatment of adult patients with primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia and in the treatment of adult patients of homozygous familial hypercholesterolemia. Version 2. Updated July 2019. Available from: https:\/\/catsalut.gencat.cat\/web\/.content\/minisite\/catsalut\/proveidors_professionals\/medicaments_farmacia\/harmonitzacio\/informes\/evolocumab\/acord-CFT-SISCAT-evolocumab-hipercolesterolemia.pdf [accessed 11.07.23]."},{"key":"10.1016\/j.medcli.2024.05.004_bib0155","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1093\/eurjpc\/zwaa097","article-title":"Safety and efficacy of alirocumab in a real-life setting: the ODYSSEY APPRISE study","volume":"28","author":"Gaudet","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.medcli.2024.05.004_bib0160","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.atherosclerosis.2017.11.027","article-title":"PCSK9 inhibitors in clinical practice: delivering on the promise?","volume":"270","author":"Stoekenbroek","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.medcli.2024.05.004_bib0165","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.cjco.2022.03.003","article-title":"Real-world insights into evolocumab use in patients with hyperlipidemia: Canadian analysis from the ZERBINI study","volume":"4","author":"Gupta","year":"2022","journal-title":"CJC Open"},{"key":"10.1016\/j.medcli.2024.05.004_bib0170","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.atherosclerosis.2023.01.001","article-title":"Efficacy, safety, adherence and persistence of PCSK9 inhibitors in clinical practice: a single country, multicenter, observational study (AT-TARGET-IT)","volume":"366","author":"Gargiulo","year":"2023","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.medcli.2024.05.004_bib0175","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.atherosclerosis.2023.01.002","article-title":"Long-term persistence with evolocumab treatment and sustained reductions in LDL-cholesterol levels over 30 months: final results from the European observational HEYMANS study","volume":"366","author":"Ray","year":"2023","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.medcli.2024.05.004_bib0180","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1007\/s12325-021-01962-w","article-title":"Effectiveness, adherence, and safety of evolocumab in a Swiss multicenter prospective observational study","volume":"39","author":"Nanchen","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.medcli.2024.05.004_bib0185","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40256-020-00411-3","article-title":"PCSK9 inhibitors in a German single-center clinical practice: real-world treatment of patients at high cardiovascular risk over 68 weeks","volume":"21","author":"Hollstein","year":"2021","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.medcli.2024.05.004_bib0190","doi-asserted-by":"crossref","first-page":"117108","DOI":"10.1016\/j.atherosclerosis.2023.03.013","article-title":"Sex differences in efficacy and safety of PCSK9 monoclonal antibodies: a real-world registry","volume":"384","author":"Galema-Boers","year":"2023","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.medcli.2024.05.004_bib0195","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/ehjcvp\/pvad009","article-title":"LDL lowering effect of PCSK9 inhibition is reduced in women","volume":"9","author":"Myasoedova","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.medcli.2024.05.004_bib0200","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jacl.2022.12.002","article-title":"Sex differences in LDL-C response to PCSK9 inhibitors: a real world experience","volume":"17","author":"Paquette","year":"2023","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.medcli.2024.05.004_bib0205","first-page":"e33044","article-title":"Protein convertase subtilisin\/kexin type 9 monoclonal antibodies (PCSK9mab) in clinical practice at secondary care \u2013 real world multicentre experience","volume":"14","author":"Bashir","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.medcli.2024.05.004_bib0210","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jacl.2018.05.012","article-title":"PCSK9 and neurocognitive function: should it be still an issue after FOURIER and EBBINGHAUS results?","volume":"12","author":"Mannarino","year":"2018","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.medcli.2024.05.004_bib0215","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10557-020-07045-2","article-title":"Impact of lowering low-density lipoprotein cholesterol with contemporary lipid-lowering medicines on cognitive function: a systematic review and meta-analysis","volume":"35","author":"Ying","year":"2021","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.medcli.2024.05.004_bib0220","unstructured":"Health quality and evaluation agency in Catalonia. Hospital care. Current situation in Catalonia. Available from: https:\/\/app.powerbi.com\/view?r=eyJrIjoiYmM5YmNkYmQtMTQ4OC00MmQwLTkwNTItMmRiYTZkODc0YWViIiwidCI6IjNiOTQyN2RjLWQzMGUtNDNiYy04YzA2LWZmNzI1MzY3NmZlYyIsImMiOjh9 [accessed 29.04.24]."}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775324003725?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775324003725?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,29]],"date-time":"2024-09-29T02:01:41Z","timestamp":1727575301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775324003725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0025775324003725"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2024.05.004","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and safety of alirocumab and evolocumab for hypercholesterolemia in a population with high cardiovascular risk","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2024.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}